Carl Gordon, OrbiMed managing partner
OrbiMed raises $4.3B across three funds to invest in biotech companies, as well as royalty deals and China startups
OrbiMed said Tuesday it has raised over $4.3 billion across three new funds to invest in public and private biotechs amid a lengthy market downturn …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
